A study in men with biochemically recurrent prostate cancer and PSA doubling time = 9 months at the time of study entry.
- AFT-47 ARACOG
A Phase II study comparing cognitive outcomes between men with non-metastatic and metastatic castration-resistant prostate cancer treated with darolutamide or enzalutamide.
- Alliance A031902 (CASPAR)
A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (Lung-Map Sub-Study)
- ECOG-ACRIN EA8183 "ERADICATE"
A Phase III Double-Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification
- ECOG-ACRIN EA8184
A Phase II Randomized Double-Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
- NRG GU008 (INNOVATE)
This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery.
- SWOG S1802
This phase III trial studies how well standard systemic therapy with or without definitive treatment works in treating participants with prostate cancer that has spread.